Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Interest Expenses (2016 - 2025)

Historic Interest Expenses for ImmunityBio (IBRX) over the last 9 years, with Q3 2025 value amounting to $15.3 million.

  • ImmunityBio's Interest Expenses fell 4797.08% to $15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.1 million, marking a year-over-year decrease of 4009.25%. This contributed to the annual value of $114.7 million for FY2024, which is 1106.3% down from last year.
  • As of Q3 2025, ImmunityBio's Interest Expenses stood at $15.3 million, which was down 4797.08% from $15.5 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Interest Expenses registered a high of $35.0 million during Q3 2023, and its lowest value of $3.2 million during Q1 2021.
  • In the last 5 years, ImmunityBio's Interest Expenses had a median value of $16.8 million in 2022 and averaged $19.4 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first soared by 53612.47% in 2022, then crashed by 4805.12% in 2025.
  • Over the past 5 years, ImmunityBio's Interest Expenses (Quarter) stood at $4.5 million in 2021, then surged by 536.12% to $28.6 million in 2022, then grew by 11.55% to $31.9 million in 2023, then fell by 18.07% to $26.1 million in 2024, then crashed by 41.55% to $15.3 million in 2025.
  • Its last three reported values are $15.3 million in Q3 2025, $15.5 million for Q2 2025, and $15.3 million during Q1 2025.